Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 14, 2023

Pembrolizumab Plus Lenvatinib as a Second- and Third-Line Therapy in Patients With Pleural Mesothelioma

The Lancet Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study
Lancet Oncol 2023 Oct 13;[EPub Ahead of Print], LH Douma, F Lalezari, V van der Noort, JF de Vries, K Monkhorst, I Smesseim, P Baas, B Schilder, M Vermeulen, JA Burgers, CJ de Gooijer

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading